GNC Launches GLP-1 Support Program
GNC, the global leader in health and wellness, today announced its unprecedented initiative to support individuals using semaglutides (GLP-1 agonists). GNC has officially become the world’s first major retailer to establish an entire section dedicated to assisting semaglutide users in managing the common side effects and challenges associated with treatment. The new support section will be featured in all 2,300-plus GNC locations across the United States.
It is estimated that 130 million Americans currently live with a condition eligible to be treated with a GLP-1 agonist, and that up to 70 million Americans may use a semaglutide by 2028. GNC’s new semaglutide support program provides a holistic supportive experience meeting the needs of semaglutide medication users for weight management, diabetes control, and heart disease.
“It has been GNC’s mission for over 85 years to help our communities achieve better health and live well,” said Michael Costello, CEO, GNC. “No matter where you are in life, no matter your age, gender or goals, GNC has always been a trusted source for support. Today, we’re staying on the forefront by supporting the millions of people around the world who are on a medical weight loss journey. The results of GLP-1 agonists are truly life-changing, but we also know that lifestyle and nutrition support are necessary companions to achieving long-term success. GNC is here to be the helping hand with our knowledgeable coaches in our stores, our science-backed products, and expert education and resources on GNC.com.”
